Bristol-myers Squibb Co. Share Price Today
(NASDAQ: BMY)

Name: Bristol-myers Squibb Co. Share Price Today (NASDAQ: BMY) - Bristol-myers Squibb Co. Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Bristol-myers Squibb Co. share price is $59.82 & ₹5,202.49 as on 6 Mar 2025, 2.30 'hrs' IST

$59.82

▲

0.38

(0.64%)

Market is closed - opens 8 PM, 06 Mar 2025

View live Bristol-myers Squibb Co. share price in Dollar and Rupees. Guide to invest in Bristol-myers Squibb Co. stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Bristol-myers Squibb Co., along with analyst recommendations, forecasts, and comprehensive financials.

Bristol-myers Squibb Co. share price movements

Today's Low: $59.42
Today's High: $60.25
$59.82
0.68%
Downside
Day's Volatility :1.39%
Upside
0.71%
52 Weeks Low: $39.35
52 Weeks High: $61.10
$59.82
34.22%
Downside
52 Weeks Volatility :35.6%
Upside
2.09%

Bristol-myers Squibb Co. (BMY) Returns

Period	Bristol-myers Squibb Co.	Sector (Health Care)	Index (Russel 2000)
3 Months	1.02%	2.1%	0.0%
6 Months	19.36%	-4.1%	0.0%
1 Year	11.35%	2.2%	0.0%
3 Years	-13.57%	11.8%	-11.6%

Bristol-myers Squibb Co. (BMY) Key Statistics

in dollars & INR

Previous Close	$59.44
Open	$59.43
Today's High	$60.25
Today's Low	$59.415
Market Capitalization	$120.6B
Today's Volume	$4.2M
52 Week High	$61.1
52 Week Low	$39.35
Revenue TTM	$48.3B
EBITDA	$19.4B
Earnings Per Share (EPS)	$-4.41
Dividend Yield	4.14%
Profit Margin	-18.53%
Quarterly Earnings Growth YOY	-0.96%
Return On Equity TTM	-38.95%

How to invest in Bristol-myers Squibb Co. Stock (BMY) from India?

It is very easy for Indian residents to invest directly in Bristol-myers Squibb Co. from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Bristol-myers Squibb Co. stock in both Indian Rupees (INR) and US Dollars (USD). Search for Bristol-myers Squibb Co. or BMY on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Bristol-myers Squibb Co. or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Bristol-myers Squibb Co. shares which would translate to 0.015 fractional shares of Bristol-myers Squibb Co. as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Bristol-myers Squibb Co., in just a few clicks!

Returns in Bristol-myers Squibb Co. (BMY) for Indian investors in Rupees

The Bristol-myers Squibb Co. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Bristol-myers Squibb Co. investment value today

Current value as on today

₹1,20,387

Returns

₹20,387

(+20.39%)

Returns from Bristol-myers Squibb Co. Stock

₹15,438 (+15.44%)

Dollar Returns

₹4,949 (+4.95%)

Indian investors sentiment towards Bristol-myers Squibb Co. (BMY)

-3%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Bristol-myers Squibb Co. Stock from India on INDmoney has decreased by -3% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Bristol-myers Squibb Co.

Vanguard Group Inc
9.36%
BlackRock Inc
7.77%
JPMorgan Chase & Co
4.73%
State Street Corp
4.69%
Charles Schwab Investment Management Inc
2.97%
Capital Research & Mgmt Co - Division 3
2.26%

Analyst Recommendation on Bristol-myers Squibb Co.

Hold

32%Buy

64%Hold

3%Sell

Based on 31 Wall street analysts offering stock ratings for Bristol-myers Squibb Co.(by analysts ranked 0 to 5 stars)

Based on 31 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Bristol-myers Squibb Co. Stock (BMY)

What analysts predicted

Upside of 2.38%

Target:

$61.24

Current:

$59.82

Insights on Bristol-myers Squibb Co. Stock (Ticker Symbol: BMY)

Price Movement
In the last 7 days, BMY stock has moved up by 3.6%
Increasing Revenue
Bristol-Myers Squibb Co. has shown positive revenue growth over the last two quarters. The company's revenue increased from $11.89 billion to $12.34 billion, resulting in an average growth rate of 3.7% per quarter.
Decreasing Net Profit
Bristol-Myers Squibb Co. has experienced a significant decline in its net profit over the last three quarters. The profit decreased from $1.68 billion to $72 million, indicating an average decrease of 61% each quarter.
BMY vs LLY (1 yr)
In the last 1 year, Eli Lilly And Company has given 17.2% return, outperforming this stock by 2.5%
BMY vs LLY (3 yr)
In the last 3 years, Eli Lilly And Company has given 246.6% return, outperforming this stock by 260.9%
Price to Sales
Bristol-Myers Squibb Co. has a Price-to-Sales (P/S) Ratio of 2.5. This means that for every $1 of sales the company generates, investors are willing to pay $2.5. In comparison, Eli Lilly and Company has a much higher P/S Ratio of 18.2, indicating that investors are willing to pay $18.2 for every $1 of sales. This suggests that investors may currently see more value or growth potential in Eli Lilly compared to Bristol-Myers Squibb.

BMY Bristol-myers Squibb Co. Financials in INR & Dollars

	FY19	Y/Y Change
Revenue	$26.1B	↑ 15.89%
Net Income	$3.4B	↓ 30.55%
Net Profit Margin	13.15%	↓ 8.8%

	FY20	Y/Y Change
Revenue	$42.5B	↑ 62.62%
Net Income	$-9.0B	↓ 361.56%
Net Profit Margin	-21.16%	↓ 34.31%

	FY21	Y/Y Change
Revenue	$46.4B	↑ 9.09%
Net Income	$7.0B	↓ 177.75%
Net Profit Margin	15.08%	↑ 36.24%

	FY22	Y/Y Change
Revenue	$46.2B	↓ 0.49%
Net Income	$6.3B	↓ 9.54%
Net Profit Margin	13.71%	↓ 1.37%

	FY23	Y/Y Change
Revenue	$45.0B	↓ 2.5%
Net Income	$8.0B	↑ 26.84%
Net Profit Margin	17.83%	↑ 4.12%

	FY24	Y/Y Change
Revenue	$48.3B	↑ 7.32%
Net Income	$-8.9B	↓ 211.5%
Net Profit Margin	-18.53%	↓ 36.36%

	Q3 FY23	Q/Q Change
Revenue	$11.0B	↓ 2.32%
Net Income	$1.9B	↓ 6.99%
Net Profit Margin	17.58%	↓ 0.89%

	Q4 FY23	Q/Q Change
Revenue	$11.5B	↑ 4.66%
Net Income	$1.8B	↓ 8.61%
Net Profit Margin	15.35%	↓ 2.23%

	Q1 FY24	Q/Q Change
Revenue	$11.9B	↑ 3.38%
Net Income	$-11.9B	↓ 775.99%
Net Profit Margin	-100.39%	↓ 115.74%

	Q2 FY24	Q/Q Change
Revenue	$12.2B	↑ 2.83%
Net Income	$1.7B	↓ 114.1%
Net Profit Margin	13.77%	↑ 114.16%

	Q3 FY24	Q/Q Change
Revenue	$11.9B	↓ 2.53%
Net Income	$1.2B	↓ 27.92%
Net Profit Margin	10.18%	↓ 3.59%

	Q4 FY24	Q/Q Change
Revenue	$12.3B	↑ 3.78%
Net Income	$72.0M	↓ 94.05%
Net Profit Margin	0.58%	↓ 9.6%

	FY19	Y/Y Change
Profit	$18.1B	↑ 12.82%

	FY20	Y/Y Change
Profit	$30.7B	↑ 70.17%

	FY21	Y/Y Change
Profit	$36.4B	↑ 18.54%

	FY22	Y/Y Change
Profit	$36.0B	↓ 1.16%

	FY23	Y/Y Change
Profit	$34.3B	↓ 4.74%

	FY24	Y/Y Change
Profit	$36.4B	↑ 5.94%

	Q3 FY23	Q/Q Change
Profit	$8.5B	↑ 1.32%

	Q4 FY23	Q/Q Change
Profit	$8.7B	↑ 3.22%

	Q1 FY24	Q/Q Change
Profit	$8.9B	↑ 2.3%

	Q2 FY24	Q/Q Change
Profit	$6.8B	↓ 23.87%

	Q3 FY24	Q/Q Change
Profit	$8.9B	↑ 31.38%

	Q4 FY24	Q/Q Change
Profit	$7.5B	↓ 15.72%

	FY19	Y/Y Change
Operating Cash Flow	$8.1B	↑ 35.81%
Investing Cash Flow	$-9.8B	↑ 1017.85%
Financing Cash Flow	$7.6B	↓ 315.59%

	FY20	Y/Y Change
Operating Cash Flow	$14.1B	↑ 74.19%
Investing Cash Flow	$-10.9B	↑ 11.15%
Financing Cash Flow	$-1.2B	↓ 115.1%

	FY21	Y/Y Change
Operating Cash Flow	$16.2B	↑ 15.34%
Investing Cash Flow	$-538.0M	↓ 95.05%
Financing Cash Flow	$-16.2B	↑ 1309.56%

	FY22	Y/Y Change
Operating Cash Flow	$13.1B	↓ 19.38%
Investing Cash Flow	$-1.1B	↑ 97.4%
Financing Cash Flow	$-17.0B	↑ 4.55%

	FY23	Y/Y Change
Operating Cash Flow	$13.9B	↑ 6.08%
Investing Cash Flow	$-2.3B	↑ 116.1%
Financing Cash Flow	$-9.4B	↓ 44.49%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$4.8B	↑ 151.78%
Investing Cash Flow	$-410.0M	↑ 24.62%
Financing Cash Flow	$-5.2B	↑ 137.46%

	Q4 FY23	Q/Q Change
Operating Cash Flow	$4.3B	↓ 10.5%
Investing Cash Flow	$-1.3B	↑ 228.29%
Financing Cash Flow	$967.0M	↓ 118.74%

	Q1 FY24	Q/Q Change
Operating Cash Flow	$2.8B	↓ 33.35%
Investing Cash Flow	$-19.6B	↑ 1357.5%
Financing Cash Flow	$14.6B	↑ 1414.37%

Bristol-myers Squibb Co. Technicals Summary

Sell

Neutral

Buy

Bristol-myers Squibb Co. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Bristol-myers Squibb Co. (BMY) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Bristol-myers Squibb Co.	-0.85%	19.36%	11.35%	-13.57%	3.09%
Eli Lilly And Company	10.29%	-0.19%	16.84%	248.21%	571.28%
Johnson & Johnson	7.77%	0.26%	3.82%	-3.94%	21.24%
Merck & Co. Inc.	-7.25%	-21.95%	-25.2%	19.08%	17.22%
Novo Nordisk A/s	5.91%	-33.15%	-29.86%	73.53%	194.37%
Abbvie Inc	9.27%	7.73%	14.75%	39.02%	143.65%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Bristol-myers Squibb Co.	12.66	NA	1.36	6.75	-0.39	0.07	0.04	8.05
Eli Lilly And Company	79.36	79.36	1.37	23.09	0.84	0.15	0.01	15.81
Johnson & Johnson	28.89	28.89	1.12	10.57	0.2	0.08	0.03	29.7
Merck & Co. Inc.	13.82	13.82	0.07	8.98	0.41	0.14	0.04	18.32
Novo Nordisk A/s	28.1	28.1	1.44	0.0	0.81	0.22	0.02	32.31
Abbvie Inc	88.86	88.86	0.44	12.27	0.62	0.08	0.03	1.88

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Bristol-myers Squibb Co.	Hold	$120.6B	3.09%	12.66	-18.53%
Eli Lilly And Company	Buy	$818.3B	571.28%	79.36	23.51%
Johnson & Johnson	Buy	$402.7B	21.24%	28.89	15.84%
Merck & Co. Inc.	Buy	$235.3B	17.22%	13.82	26.67%
Novo Nordisk A/s	Buy	$393.1B	194.37%	28.1	34.78%
Abbvie Inc	Buy	$373.3B	143.65%	88.86	7.59%

Bristol-myers Squibb Co. Dividend announcements

Bristol-myers Squibb Co. Dividends June, 2025
In the quarter ending June,2025. Bristol-myers Squibb Co. has declared dividend of $0.62

About Bristol-myers Squibb Co.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel to treat patients with Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of relapsed/refractory multiple myeloma; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Reblozyl to treat anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Cobenfy to treat schizophrenia in adults; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; and Abraxane for the treatment of breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Organization	Bristol-myers Squibb Co.
Employees	34100
CEO	Dr. Christopher S. Boerner Ph.D.
Industry	Health Technology

Management People of Bristol-myers Squibb Co.

Name	Title
Dr. Christopher S. Boerner Ph.D.	CEO & Chairman
Mr. David V. Elkins	Executive VP & CFO
Ms. Sandra Leung Esq.	Executive VP & General Counsel
Mr. Samit Hirawat M.D.	Executive VP, Chief Medical Officer & Head of Development
Mr. Greg Meyers	Executive VP and Chief Digital & Technology Officer
Ms. Kimberly M. Jablonski	Chief Compliance & Ethics Officer
Ms. Ahn Amanda Poole	Executive Vice President & Chief Human Resources Officer
Dr. Joseph J. Eiden Jr.	Head of Medical Affairs
Mr. Adam Lenkowsky	Executive VP, Chief Commercialization Officer & Head of U.S. Oncology
Ms. Catherine E. Owen Adams	Senior Vice President of Major Markets

Important FAQs about investing in BMY Stock from India :

What is Bristol-myers Squibb Co. share price today?

Bristol-myers Squibb Co. share price today stands at $59.82, Open: $59.43 ; Previous Close: $59.44 ; High: $60.25 ; Low: $59.42 ; 52 Week High: $61.10 ; 52 Week Low: $39.35.

The stock opens at $59.43, after a previous close of $59.44. The stock reached a daily high of $60.25 and a low of $59.42, with a 52-week high of $61.10 and a 52-week low of $39.35.

Can Indians buy Bristol-myers Squibb Co. shares?

Yes, Indians can invest in the Bristol-myers Squibb Co. (BMY) from India.

With INDmoney, you can buy Bristol-myers Squibb Co. at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Bristol-myers Squibb Co. at zero transaction cost.

How can I buy Bristol-myers Squibb Co. shares from India?

It is very easy to buy Bristol-myers Squibb Co. from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Bristol-myers Squibb Co. (BMY) be purchased?

Yes, you can buy fractional shares of Bristol-myers Squibb Co. with INDmoney app.

What are the documents required to start investing in Bristol-myers Squibb Co. stocks?

To start investing in Bristol-myers Squibb Co., You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.